AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Aardvark Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$3.74−0.04 (-1.06%)

Close on Oct 19, 2026

Market cap: $81.70M
P/E (TTM): –
Dividend yield: –

Aardvark Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31
Cash & Equivalents	74	62	47	39	26	27	62	82	86	7.54	9.74
Short-Term Investments	0.02	29	63	87	116	125	12	–	–	–	–
Cash & Short-Term Investments	74	91	110	126	142	151	74	82	86	7.54	9.74
Prepaid Expenses & Other	6.79	2.38	1.86	2.86	2.95	3.29	0.47	–	–	–	–
Total Current Assets	81	94	112	129	145	155	74	–	–	–	–
Operating Lease Right-of-Use Assets	0.63	0.27	0.36	0.44	0.52	0.63	0.74	–	–	–	–
Other Long-Term Assets	0.17	4.74	4.94	3.58	2.19	1.84	2.64	–	–	–	–
Total Assets	81	99	117	133	147	157	78	–	–	–	–
Accounts Payable	2.09	4.49	2.07	4.44	5.06	2.56	2.30	–	–	–	–
Accrued Expenses	3.90	6.78	8.04	5.86	4.84	3.03	2.29	–	–	–	–
Current Portion of Leases	0.40	0.34	0.44	0.43	0.42	0.39	0.34	–	–	–	–
Total Current Liabilities	6.39	12	11	11	10	5.98	4.93	–	–	–	–
Long-Term Leases	0.28	–	0	0.12	0.23	0.34	0.44	–	–	–	–
Operating Lease Liabilities	0.68	0.34	0.44	0.55	0.65	0.73	0.78	–	–	–	–
Other Long-Term Liabilities	–	–	0	0	0.01	0.02	0.03	–	–	–	–
Total Liabilities	6.66	12	11	11	11	6.34	5.39	–	–	–	–
Preferred Stock	0	0	0	0	0	0	0	–	–	–	–
Common Stock	0	0	0	0	0	0	0	–	–	–	–
Additional Paid-In Capital	227	224	222	221	219	218	3.68	–	–	–	–
Retained Earnings	-152	-138	-116	-98	-82	-68	-58	–	–	–	–
Comprehensive Income & Other	0	0.01	0.08	0.08	0.00	0.04	0	–	–	–	–
Shareholders' Equity	75	87	107	122	137	151	-55	-46	-42	-37	-35
Total Equity	75	87	107	122	137	151	-55	-46	-42	-37	-35
Total Liabilities & Equity	81	99	117	133	147	157	78	–	–	–	–
Shares Outstanding(shares)	22	22	22	22	22	22	4.07	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -221.5%

Financial strength

Current ratio: 12.63
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1156.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.09
Dividend yield: –